A multicenter, prospective epidemiologig study of the progression of geographic atropy secondary to age-related magular degeneration

A phase III, multicenter, randomized, double-masked, sham-controlled study to assess the efficacy and safety of lamipalizumab administered intravitreally to patients with geographic atrophy secondary to age-related miacular degeneration

A Phase III, open-label, randomized Study of MPDL3280A (Anti-PD-L1 antibody) in combination with bevacizumab versus sunitinib in patients with untreated advanced renal cell carcinoma

A prospective, open-label, multicenter, randomized phase III trial to compare the efficacy and safety of a combined regimen of obinutuzumab and GDC-0199 (ABT-199) versus obinutuzumab and chlorambucil in previously untreated patients with CLL and coexisting medical conditions

A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)

Eine offene, multizentrische, randomisisierte Studie der Phase III zur Untersuchung der Wirk-samkeit und Sicherheit von MPDL3280A (anti-PD-L1 Antikörper) im Vergleich mit Chemothe-rapie bei Patienten mit lokal fortgeschrittenem oder metastasiertem Urothelkarzinom der Harn-blase nach Versagen einer platinhaltigen Chemotherapie

ENSEMBLE – AN OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATETHE EFFECTIVENESS AND SAFETY OFOCRELIZUMAB IN PATIENTS WITH EARLY STAGERELAPSING REMITTING MULTIPLE SCLEROSIS

Toffife – Tocilizumab for the Treatment of Familial Mediterranean Fever

Trilogy – A PHASE III, DOUBLE-BLINDED, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB PLUS COBIMETINIB AND VEMURAFENIB VERSUS PLACEBO PLUS COBIMETINIB AND VEMURAFENIB IN PREVIOUSLY UNTREATED BRAFV600 MUTATION−POSITIVE PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA